Who Paid My Doc
Rylaze
Drug Hematology/Oncology
NDC 68727-900-03
General payments
$3,188,167
Research payments
$8,217,689
Through program year 2025, $3,188,167 in general payments and $8,217,689 in research payments were reported against Rylaze (Hematology/Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $956,718 | 1,818 |
| 2025 | Research | $891,137 | 9 |
| 2024 | General | $896,479 | 1,745 |
| 2024 | Research | $431,671 | 7 |
| 2023 | General | $628,880 | 1,288 |
| 2023 | Research | $833,975 | 70 |
| 2022 | General | $498,223 | 929 |
| 2022 | Research | $2,515,835 | 197 |
| 2021 | General | $207,867 | 325 |
| 2021 | Research | $3,545,071 | 123 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 44 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 43 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
6,105 general · 406 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.